Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Anne Hu, Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison T. Jess, Pei-Shun Li, Karen I. Kroeker, Brendan P. Halloran, Remo Panaccione, Laurent Peyrin‐Biroulet, Christopher Ma, Ashwin N. Ananthakrishnan
Topics & Concepts
MedicineVedolizumabUstekinumabInternal medicineGastroenterologyInflammatory bowel diseaseInflammatory Bowel DiseasesAdalimumabTumor necrosis factor alphaDiseaseInflammatory Bowel DiseaseLiver Diseases and ImmunityBiosimilars and Bioanalytical Methods